相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
Caryl J. Schwartzbach et al.
JOURNAL OF NEUROLOGY (2017)
Slowly eroding lesions in multiple sclerosis
Varun Sethi et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
Maria Pia Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome
W. J. Brownlee et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Slowly eroding lesions in multiple sclerosis
Varun Sethi et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
Maria Pia Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome
W. J. Brownlee et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Tomas Kalincik et al.
LANCET NEUROLOGY (2017)
Gadolinium deposition in the brain: summary of evidence and recommendations
Vikas Gulani et al.
LANCET NEUROLOGY (2017)
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Johannes Lorscheider et al.
NEUROLOGY (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis
Michael G. Dwyer et al.
NEUROIMAGE-CLINICAL (2017)
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis
A. Traboulsee et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2016)
Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis
Benedetta Bodini et al.
ANNALS OF NEUROLOGY (2016)
Neuroinflammatory component of gray matter pathology in multiple sclerosis
Elena Herranz et al.
ANNALS OF NEUROLOGY (2016)
Long-Term Evolution of Multiple Sclerosis Disability in the Treatment Era
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2016)
In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents
Enrico Tedeschi et al.
EUROPEAN RADIOLOGY (2016)
Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics
Angela Vidal-Jordana et al.
JOURNAL OF NEUROIMAGING (2016)
LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY
Andreas-Antonios Roussakis et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold L. Atkins et al.
LANCET (2016)
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial
Rhian Raftopoulos et al.
LANCET NEUROLOGY (2016)
Gadolinium deposition in the brain
Tomonori Kanda et al.
MAGNETIC RESONANCE IMAGING (2016)
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)
Roberta Lanzillo et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - Commentary
Declan Chard
MULTIPLE SCLEROSIS JOURNAL (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - YES
Robert Zivadinov et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - NO
Frederik Barkhof
MULTIPLE SCLEROSIS JOURNAL (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Inclusion of brain volume loss in a revised measure of no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Assessing response to interferon-β in a multicenter dataset of patients with MS
Maria Pia Sormani et al.
NEUROLOGY (2016)
Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load
D. Pareto et al.
NEURORADIOLOGY (2016)
Real-life experience with fampridine (Fampyra (R)) for patients with multiple sclerosis and gait disorders
Yara Dadalti Fragoso et al.
NEUROREHABILITATION (2016)
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)
Roberta Lanzillo et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - Commentary
Declan Chard
MULTIPLE SCLEROSIS JOURNAL (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - YES
Robert Zivadinov et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - NO
Frederik Barkhof
MULTIPLE SCLEROSIS JOURNAL (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Inclusion of brain volume loss in a revised measure of no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Reliable measurements of brain atrophy in individual patients with multiple sclerosis
Dirk Smeets et al.
BRAIN AND BEHAVIOR (2016)
Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes
Pekka Poutiainen et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2016)
Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study
Shiv Saidha et al.
ANNALS OF NEUROLOGY (2015)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
Defining high, medium and low impact prognostic factors for developing multiple sclerosis
Mar Tintore et al.
BRAIN (2015)
Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy
Angela Vidal-Jordana et al.
JOURNAL OF NEUROLOGY (2015)
ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
Robert C. Sergott et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process
Alex Rovira et al.
NATURE REVIEWS NEUROLOGY (2015)
Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations
Kunio Nakamura et al.
NEUROIMAGE (2015)
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
David H. Miller et al.
NEUROLOGY (2015)
Can leptomeningeal enhancement be linked to multiple sclerosis?
Frederik Barkhof et al.
NEUROLOGY (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
L. Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial
Claire M. Rice et al.
TRIALS (2015)
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis A Randomized Clinical Trial
Jeffrey Cohen et al.
JAMA NEUROLOGY (2015)
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) A 3-Year Interim Report
Richard A. Nash et al.
JAMA NEUROLOGY (2015)
Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis
Carsten Lukas et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Disability in Multiple Sclerosis
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2014)
Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?
Massimo Filippi et al.
CURRENT OPINION IN NEUROLOGY (2014)
Clinical Trials to Clinical Use: Using Vision as a Model for Multiple Sclerosis and Beyond
Laura J. Balcer
JOURNAL OF NEURO-OPHTHALMOLOGY (2014)
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
Douglas L. Arnold et al.
JOURNAL OF NEUROLOGY (2014)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
Joachim Burman et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
Jeremy Chataway et al.
LANCET (2014)
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
Aaron E. Miller et al.
LANCET NEUROLOGY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis
Judith M. Sonder et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Patrick Vermersch et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Composite end points to assess delay of disability progression by MS treatments
J. Zhang et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes
Raquel Mitjana et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
Luca Massacesi et al.
PLOS ONE (2014)
Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial
Melissa Cambron et al.
TRIALS (2014)
Disease Activity Free Status A New End Point for a New Era in Multiple Sclerosis Clinical Research?
Carolyn J. Bevan et al.
JAMA NEUROLOGY (2014)
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
Omar Khan et al.
ANNALS OF NEUROLOGY (2013)
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Fred D. Lublin et al.
ANNALS OF NEUROLOGY (2013)
Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis
Yvonne C. Learmonth et al.
BMC NEUROLOGY (2013)
Sodium accumulation is associated with disability and a progressive course in multiple sclerosis
David Paling et al.
BRAIN (2013)
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis
H. Vrenken et al.
JOURNAL OF NEUROLOGY (2013)
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
John Zajicek et al.
LANCET NEUROLOGY (2013)
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Maria Pia Sormani et al.
LANCET NEUROLOGY (2013)
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
Angela Vidal-Jordana et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy
Lindsay Horton et al.
NEUROLOGY (2013)
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
Marco A. Zarbin et al.
OPHTHALMOLOGY (2013)
Dangers of non-specific composite outcome measures in clinical trials
David Prieto-Merino et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Making the Best Match: Selecting Outcome Measures for Clinical Trials and Outcome Studies
Wendy J. Coster
AMERICAN JOURNAL OF OCCUPATIONAL THERAPY (2013)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2012)
Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
D. W. Langdon et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS
Robert J. Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials
Frederik Barkhof et al.
NATURE REVIEWS NEUROLOGY (2012)
NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain
Hui Zhang et al.
NEUROIMAGE (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases
Alex Sik Chung Ching et al.
INSIGHTS INTO IMAGING (2012)
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Giancarlo Comi et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Paced auditory serial addition test (PASAT) A very difficult test even for individuals with high intellectual capability
Joseph Bruno Bidin Brooks et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2011)
The changing face of multiple sclerosis clinical trial populations
Bernard M. J. Uitdehaag et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A. Novotna et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
Per Soelberg Sorensen et al.
LANCET NEUROLOGY (2011)
Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis
C. Tur et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
M. P. Sormani et al.
NEUROLOGY (2011)
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
M. S. Freedman et al.
NEUROLOGY (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
Raju Kapoor et al.
LANCET NEUROLOGY (2010)
Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?
R. Pelayo et al.
MULTIPLE SCLEROSIS (2010)
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
L. V. A. E. Bosma et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
N. De Stefano et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Fatigue Impact Scale
J. Frith et al.
OCCUPATIONAL MEDICINE-OXFORD (2010)
Magnetic Resonance Imaging as a Potential Surrogate for Relapses in Multiple Sclerosis: A Meta-analytic Approach
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2009)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
Andrew D. Goodman et al.
LANCET (2009)
A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
X. Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)
L. C. Doward et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Predicting responders to therapies for multiple sclerosis
Jordi Rio et al.
NATURE REVIEWS NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Gray matter atrophy in multiple sclerosis: A longitudinal study
Elizabeth Fisher et al.
ANNALS OF NEUROLOGY (2008)
Gray matter atrophy is related to long-term disability in multiple sclerosis
Leonora K. Fisniku et al.
ANNALS OF NEUROLOGY (2008)
Multiple sclerosis: An immune or neurodegenerative disorder?
Bruce D. Trapp et al.
ANNUAL REVIEW OF NEUROSCIENCE (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis
P. Jung et al.
MULTIPLE SCLEROSIS (2008)
Disability as an outcome in MS clinical trials
G. C. Ebers et al.
NEUROLOGY (2008)
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS
J. J. Kragt et al.
NEUROLOGY (2008)
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations
Jeremy C. Hobart et al.
LANCET NEUROLOGY (2007)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
D. H. Miller et al.
NEUROLOGY (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
The Rao's Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population
M. P. Amato et al.
MULTIPLE SCLEROSIS (2006)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
A rapid screening tool for fatigue impact in multiple sclerosis
Daphne Kos et al.
BMC NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients
J Río et al.
ANNALS OF NEUROLOGY (2006)
Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)
JC Hobart et al.
BRAIN (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Within session practice effects on the PASAT in clients with multiple sclerosis
SL Barker-Collo
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY (2005)
The multiple sclerosis functional composite: different practice effects in the three test components
A Solari et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis
O Andersen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial
OR Hommes et al.
LANCET (2004)
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
K Schmierer et al.
ANNALS OF NEUROLOGY (2004)
Effect of relapses on development of residual deficit in multiple sclerosis
FD Lublin et al.
NEUROLOGY (2003)
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
J Zajicek et al.
LANCET (2003)
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals
F Cotton et al.
NEUROLOGY (2003)
Measuring the impact of MS on walking ability - The 12-Item MS Walking Scale (MSWS-12)
JC Hobart et al.
NEUROLOGY (2003)
Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial
H Panitch et al.
NEUROLOGY (2002)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis
SM Smith et al.
NEUROIMAGE (2002)
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
David H. Miller et al.
BRAIN (2002)
Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b
S Narayanan et al.
JOURNAL OF NEUROLOGY (2001)
Visual and motor evoked potentials in the course of multiple sclerosis
P Fuhr et al.
BRAIN (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Randomized controlled trial of interferon-beta-1a in secondary progressive MS - MRI results
DKB Li et al.
NEUROLOGY (2001)
Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study
G Comi et al.
LANCET (2001)
Normalized accurate measurement of longitudinal brain change
SM Smith et al.
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2001)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
G Comi et al.
ANNALS OF NEUROLOGY (2001)
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
PD Molyneux et al.
BRAIN (2000)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Linomide in relapsing and secondary progressive MS - Part I: Trial design and clinical results
JH Noseworthy et al.
NEUROLOGY (2000)
Linomide in relapsing and secondary progressive MS -: Part II:: MRI results
JS Wolinsky et al.
NEUROLOGY (2000)
分享论文
